Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback